FrancophonIA/ELRC3.0 huggingface dataset:
English: Jinarc 30 mg tablets + Jinarc 60 mg tablets Each 30 mg tablet contains 30 mg of tolvaptan.
Estonian: Jinarc 30 mg tabletid + Jinarc 60 mg tabletid Üks 30 mg tablett sisaldab 30 mg tolvaptaani.
English: At baseline, patients had average estimated glomerular filtration rate (eGFR) of 82 mL/min/1.73 m2 (CKD-EPI) with 79 % having hypertension and a mean TKV of
Estonian: Patsientidel oli ravi algul hinnanguline keskmine glomeerulite filtratsioonikiirus (eGFR) 82 ml/min/1,73 m
English: Nocturia, Pollakiuria, Polyuria
Estonian: Noktuuria Pollakisuuria Polüuuria
English: Jinarc 60 mg tablets + Jinarc 30 mg tablets: blisters with or without wallet card with 14 (7 tablets of the higher strength + 7 tablets of the lower strength), 28 (14 tablets of the higher strength + 14 tablets of the lower strength) or 56 (28 tablets of the higher strength + 28 tablets of the lower strength) tablets.
Estonian: Jinarc 60 mg tabletid + Jinarc 30 mg tabletid: blistrid koos voldikpakendiga või ilma 14 (7 suurema tugevusega tabletti + 7 väiksema tugevusega tabletti), 28 (14 suurema tugevusega tabletti + 14 väiksema tugevusega tabletti) või 56 (28 suurema tugevusega tabletti + 28 väiksema tugevusega tabletti) tabletiga.
English: Each Jinarc 60 mg tablet contains 60 mg tolvaptan.
Estonian: Üks Jinarc 60 mg tablett sisaldab 60 mg tolvaptaani.
English: 2) medically significant kidney pain (defined as requiring prescribed leave, last-resort analgesics,
Estonian: 1) neerufunktsiooni halvenemine (mida määratleti seerumi kreatiniinitaseme pöördväärtuse püsiva
English: Jinarc 90 mg tablets + Jinarc 30 mg tablets: blisters with or without wallet card with 14 (7 tablets of the higher strength + 7 tablets of the lower strength), 28 (14 tablets of the higher strength + 14 tablets of the lower strength) or 56 (28 tablets of the higher strength + 28 tablets of the lower strength) tablets.
Estonian: Jinarc 90 mg tabletid + Jinarc 30 mg tabletid: blistrid koos voldikpakendiga või ilma 14 (7 suurema tugevusega tabletti + 7 väiksema tugevusega tabletti), 28 (14 suurema tugevusega tabletti + 14 väiksema tugevusega tabletti) või 56 (28 suurema tugevusega tabletti + 28 väiksema tugevusega tabletti) tabletiga.
English: The treatment difference in eGFR change observed in this trial is 1.27 mL/min/1.73 m 2, representing a
Estonian: Selles uuringus täheldatud eGFR-i muutuse erinevus on 1,27 ml/min/1,73 m2, moodustades 35%-lise vähenemise muutuse vähimruutude meetodil (LS) eGFR-is -2,34 ml/min/1,73 m2 tolvaptaani rühmas võrreldes
English: Jinarc 30 mg tablets + Jinarc 90 mg tablets Each 30 mg tablet contains 30 mg of tolvaptan.
Estonian: Jinarc 30 mg tabletid + Jinarc 90 mg tabletid Üks 30 mg tablett sisaldab 30 mg tolvaptaani.
English: Each Jinarc 30 mg tablet contains 30 mg tolvaptan.
Estonian: Üks Jinarc 30 mg tablett sisaldab 30 mg tolvaptaani.
English: Each Jinarc 15 mg tablet contains 15 mg tolvaptan.
Estonian: Üks Jinarc 15 mg tablett sisaldab 15 mg tolvaptaani.
English: 45 mg tablet: blue, square (6.8 mm on a side, major axis 8.2 mm), shallow-convex, debossed with “OTSUKA” and “45” on one side
Estonian: 45 mg tablett: sinine, nelinurkne (üks külg 6,8 mm, pikem külg 8,2 mm), veidi kumer, ühel küljel on pimetrükk „OTSUKA” ja „45”.
English: Tolvaptan may cause hyperglycaemia (see section 4.8).
Estonian: Tolvaptaan võib kutsuda esile hüperglükeemia (vt lõik 4.8).
English: Jinarc 15 mg tablets
Estonian: Jinarc 15 mg tabletid
English: Each Jinarc 45 mg tablet contains 45 mg tolvaptan.
Estonian: Üks Jinarc 45 mg tablett sisaldab 45 mg tolvaptaani.
English: Each Jinarc 90 mg tablet contains 90 mg tolvaptan.
Estonian: Üks Jinarc 90 mg tablett sisaldab 90 mg tolvaptaani.
English: 60 mg tablet: blue, modified rectangular (major axis 9.9 mm, minor axis 5.6 mm), shallow-convex, debossed with “OTSUKA” and “60” on one side
Estonian: 60 mg tablett: sinine, modifitseeritud ristküliku kujuline (pikem külg 9,9 mm, lühem külg 5,6 mm), veidi kumer, ühel küljel on pimetrükk „OTSUKA” ja „60”.
English: 90 mg tablet: blue, pentagonal (major axis 9.7 mm, minor axis 9.5 mm), shallow-convex, debossed with “OTSUKA” and “90” on one side
Estonian: 90 mg tablett: sinine, viisnurkne (pikem külg 9,7 mm, lühem külg 9,5 mm), veidi kumer, ühel küljel on pimetrükk „OTSUKA” ja „90”.
English: Acute reductions in mean total kidney volume were also observed following 3 weeks of therapy in all CKD stages, ranging from -4.6 % for CKD stage 1 to -1.9 % for CKD stage 4.
Estonian: −4,6 %-st kroonilise neeruhaiguse 1. astmel kuni −1,9 %-ni 4. astmel.
English: Each 60 mg tablet contains 60 mg tolvaptan.
Estonian: Üks 60 mg tablett sisaldab 60 mg tolvaptaani.
English: Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential.
Estonian: Farmakoloogilise ohutuse, korduvtoksilisuse, genotoksilisuse ja kartsinogeensuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: Each 30 mg tablet contains 30 mg tolvaptan.
Estonian: Üks 30 mg tablett sisaldab 30 mg tolvaptaani.
English: 35 % reduction in the LS means of change in eGFR of -2.34 mL/min/1.73 m in tolvaptan group relative to a -3.61 mL/min/1.73 m in placebo group observed over the course of one year.
Estonian: 3,61 ml/min/1,73 m platseeborühmas, mida täheldati ühe aasta jooksul.
English: Blue, triangular (major axis: 6.58 mm, minor axis: 6.20 mm), shallow-convex, debossed with “OTSUKA” and “15” on one side.
Estonian: Sinine, kolmnurkne (pikem külg: 6,58 mm, lühem külg: 6,20 mm), veidi kumer, ühel küljel on pimetrükk „OTSUKA” ja „15”.
English: 15 mg tablet: blue, triangular (major axis: 6.58 mm, minor axis: 6.20 mm), shallow-convex, debossed with “OTSUKA” and “15” on one side.
Estonian: 15 mg tablett: sinine, kolmnurkne (pikem külg 6,58 mm, lühem külg 6,20 mm), veidi kumer, ühel küljel on pimetrükk „OTSUKA” ja „15”.
English: Each 45 mg tablet contains 45 mg of tolvaptan.
Estonian: Üks 45 mg tablett sisaldab 45 mg tolvaptaani.
English: Jinarc 15 mg tablets + Jinarc 45 mg tablets
Estonian: Jinarc 15 mg tabletid + Jinarc 45 mg tabletid
English: The no observed adverse effect level (NOAEL) for effects on reproduction in females (100 mg/kg/day) was about 8-times the maximum human recommended dose of 120 mg/day on a mg/m basis.
Estonian: Emasloomade reproduktsioonile avalduvate kõrvaltoimeteta tase (100 mg/kg ööpäevas) oli ligikaudu
English: Each 90 mg tablet contains 90 mg of tolvaptan.
Estonian: Üks 90 mg tablett sisaldab 90 mg tolvaptaani.
English: Jinarc 15 mg tablets Jinarc 45 mg tablets tolvaptan
Estonian: Jinarc 15 mg tabletid Jinarc 45 mg tabletid
English: EU/1/15/1000/005 14 tablets (7 × 15 mg + 7 × 45 mg) EU/1/15/1000/006 28 tablets (14 × 15 mg + 14 × 45 mg) EU/1/15/1000/007 56 tablets (28 × 15 mg + 28 × 45 mg)
Estonian: EU/1/15/1000/005 14 tabletti (7 × 15 mg + 7 × 45 mg) EU/1/15/1000/006 28 tabletti (14 × 15 mg + 14 × 45 mg) EU/1/15/1000/007 56 tabletti (28 × 15 mg + 28 × 45 mg)
English: 7 × 15 mg tablets and 7 × 45 mg tablets in card packaging 14 × 15 mg tablets and 14 × 45 mg tablets in card packaging 28 × 15 mg tablets and 28 × 45 mg tablets in card packaging
Estonian: 7 × 15 mg tabletti ja 7 × 45 mg tabletti voldikpakendis 14 × 15 mg tabletti ja 14 × 45 mg tabletti voldikpakendis 28 × 15 mg tabletti ja 28 × 45 mg tabletti voldikpakendis
English: Tolvaptan is not recommended in the paediatric age group.
Estonian: Tolvaptaani kasutamine laste vanuserühmas ei ole soovitatav.
English: Very common Common
Estonian: • üldine nõrkustunne
English: Tolvaptan has not been extensively studied in ADPKD in combination with diuretics.
Estonian: Tolvaptaani kasutamist autosoom-dominantse polütsüstilise neeruhaiguse raviks koos diureetikumidega ei ole ulatuslikult uuritud.
English: 7 × 30 mg tablets and 7 × 90 mg tablets 14 × 30 mg tablets and 14 × 90 mg tablets 28 × 30 mg tablets and 28 × 90 mg tablets
Estonian: 7 × 30 mg tabletti ja 7 × 90 mg tabletti 14 × 30 mg tabletti ja 14 × 90 mg tabletti 28 × 30 mg tabletti ja 28 × 90 mg tabletti
English: EU/1/15/1000/014 14 tablets (7 × 15 mg + 7 × 45 mg) EU/1/15/1000/015 28 tablets (14 × 15 mg + 14 × 45 mg) EU/1/15/1000/016 56 tablets (28 × 15 mg + 28 × 45 mg)
Estonian: EU/1/15/1000/014 14 tabletti (7 × 15 mg + 7 × 45 mg) EU/1/15/1000/015 28 tabletti (14 × 15 mg + 14 × 45 mg) EU/1/15/1000/016 56 tabletti (28 × 15 mg + 28 × 45 mg)
English: Talk to your doctor before taking Jinarc
Estonian: Enne Jinarci võtmist pidage nõu oma arstiga:
English: Jinarc 30 mg tablets + Jinarc 60 mg tablets
Estonian: Jinarc 30 mg tabletid + Jinarc 60 mg tabletid
English: 7 × 30 mg tablets and 7 × 60 mg tablets 14 × 30 mg tablets and 14 × 60 mg tablets 28 × 30 mg tablets and 28 × 60 mg tablets
Estonian: 7 × 30 mg tabletti ja 7 × 60 mg tabletti 14 × 30 mg tabletti ja 14 × 60 mg tabletti 28 × 30 mg tabletti ja 28 × 60 mg tabletti
English: Each tablet contains 15 mg tolvaptan.
Estonian: Üks tablett sisaldab 15 mg tolvaptaani.
English: Jinarc 30 mg tablets + Jinarc 90 mg tablets
Estonian: Jinarc 30 mg tabletid + Jinarc 90 mg tabletid
English: Jinarc may cause your liver not to work properly.
Estonian: Jinarc võib põhjustada maksa talitlushäireid.
English: See leaflet for further information.
Estonian: Täpsem teave on esitatud pakendi infolehel.
English: Each tablet contains 30 mg tolvaptan.
Estonian: Üks tablett sisaldab 30 mg tolvaptaani.
English: Diabetes mellitus
Estonian: Lihasspasmid
English: Jinarc 15 mg tablets + Jinarc 45 mg tablets 14 tablets in 1 PVC/aluminium foil blister with 7 × 15 mg and 7 × 45 mg tablets 28 tablets in 2 PVC/aluminium foil blisters with 7 × 15 mg and 7 × 45 mg tablets 56 tablets in 4 PVC/aluminium foil blisters with 7 × 15 mg and 7 × 45 mg tablets
Estonian: 14 tabletti 1 PVC/alumiiniumfooliumist blistris 7 × 15 mg ja 7 × 45 mg tabletiga 28 tabletti 2 PVC/alumiiniumfooliumist blistris 7 × 15 mg ja 7 × 45 mg tabletiga 56 tabletti 4 PVC/alumiiniumfooliumist blistris 7 × 15 mg ja 7 × 45 mg tabletiga
English: • itching
Estonian: • isutus
English: Anaphylaxis
Estonian: Imendumine
English: EU/1/15/1000/008 14 tablets (7 × 30 mg + 7 × 60 mg) EU/1/15/1000/009 28 tablets (14 × 30 mg + 14 × 60 mg) EU/1/15/1000/010 56 tablets (28 × 30 mg + 28 × 60 mg)
Estonian: EU/1/15/1000/008 14 tabletti (7 × 30 mg + 7 × 60 mg) EU/1/15/1000/009 28 tabletti (14 × 30 mg + 14 × 60 mg) EU/1/15/1000/010 56 tabletti (28 × 30 mg + 28 × 60 mg)
English: Jinarc 30 mg tablets Jinarc 60 mg tablets tolvaptan
Estonian: Jinarc 30 mg tabletid Jinarc 60 mg tabletid
English: Jinarc 30 mg tablets Jinarc 90 mg tablets tolvaptan
Estonian: Jinarc 30 mg tabletid Jinarc 90 mg tabletid
English: Each 15 mg tablet contains approximately 35 mg lactose (as monohydrate).
Estonian: Teadaolevat toimet omav(ad) abiaine(d) Üks 15 mg tablett sisaldab ligikaudu 35 mg laktoosi (monohüdraadina).
English: Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 555
Estonian: Tél/Tel: +31 (0) 20 85 46 555
English: Serum sodium abnormalities
Estonian: Seerumi naatriumisisalduse kõrvalekalded
English: A reversible reduction in GFR has been observed in ADPKD trials at the initiation of tolvaptan treatment.
Estonian: Autosoom-dominantse polütsüstilise neeruhaiguse uuringutes on täheldatud ravi alustamisel tolvaptaaniga glomeerulite filtratsioonikiiruse pöörduvat vähenemist.
English: EU/1/15/1000/020 14 tablets (7 × 30 mg + 7 × 90 mg) EU/1/15/1000/021 28 tablets (14 × 30 mg + 14 × 90 mg) EU/1/15/1000/022 56 tablets (28 × 30 mg + 28 × 90 mg)
Estonian: EU/1/15/1000/020 14 tabletti (7 × 30 mg + 7 × 90 mg) EU/1/15/1000/021 28 tabletti (14 × 30 mg + 14 × 90 mg) EU/1/15/1000/022 56 tabletti (28 × 30 mg + 28 × 90 mg
English: EU/1/15/1000/011 14 tablets (7 × 30 mg + 7 × 90 mg) EU/1/15/1000/012 28 tablets (14 × 30 mg + 14 × 90 mg) EU/1/15/1000/013 56 tablets (28 × 30 mg + 28 × 90 mg)
Estonian: EU/1/15/1000/011 14 tabletti (7 × 30 mg + 7 × 90 mg) EU/1/15/1000/012 28 tabletti (14 × 30 mg + 14 × 90 mg) EU/1/15/1000/013 56 tabletti (28 × 30 mg + 28 × 90 mg
English: Otsuka Pharmaceutical Netherlands B.V. Teл: +31 (0) 20 85 46 555
Estonian: Teл: +31 (0) 20 85 46 555
English: EU/1/15/1000/017 14 tablets (7 × 30 mg + 7 × 60 mg) EU/1/15/1000/018 28 tablets (14 × 30 mg + 14 × 60 mg) EU/1/15/1000/019 56 tablets (28 × 30 mg + 28 × 60 mg)
Estonian: EU/1/15/1000/017 14 tabletti (7 × 30 mg + 7 × 60 mg) EU/1/15/1000/018 28 tabletti (14 × 30 mg + 14 × 60 mg) EU/1/15/1000/019 56 tabletti (28 × 30 mg + 28 × 60 mg)
English: • gout
Estonian: • lööve
English: The active substance is tolvaptan.
Estonian: Mida Jinarc sisaldab Toimeaine on tolvaptaan.
English: België/Belgique/Belgien Otsuka Pharmaceutical Netherlands B.V. Tél/Tel: +31 (0) 20 85 46 555
Estonian: België/Belgique/Belgien Otsuka Pharmaceutical Netherlands B.V.
English: • nausea
Estonian: • nahakihelus
English: • fatigue
Estonian: • unehäired
English: Abdominal pain, Abdominal distension, Constipation, Dyspepsia,
Estonian: Farmakodünaamiliselt prognoositavad ja kõige sagedamini esinevad kõrvaltoimed on janu, polüuuria,
English: 7 × 30 mg tablets and 7 × 90 mg tablets in card packaging 14 × 30 mg tablets and 14 × 90 mg tablets in card packaging 28 × 30 mg tablets and 28 × 90 mg tablets in card packaging
Estonian: 7 × 30 mg tabletti ja 7 × 90 mg tabletti voldikpakendis 14 × 30 mg tabletti ja 14 × 90 mg tabletti voldikpakendis 28 × 30 mg tabletti ja 28 × 90 mg tabletti voldikpakendis
English: Jinarc 30 mg tablets + Jinarc 90 mg tablets 14 tablets in 1 PVC/aluminium foil blister with 7 × 30 mg and 7 × 90 mg tablets 28 tablets in 2 PVC/aluminium foil blisters with 7 × 30 mg and 7 × 90 mg tablets 56 tablets in 4 PVC/aluminium foil blisters with 7 × 30 mg and 7 × 90 mg tablets
Estonian: 14 tabletti 1 PVC/alumiiniumfooliumist blistris 7 × 30 mg ja 7 × 90 mg tabletiga 28 tabletti 2 PVC/alumiiniumfooliumist blistris 7 × 30 mg ja 7 × 90 mg tabletiga 56 tabletti 4 PVC/alumiiniumfooliumist blistris 7 × 30 mg ja 7 × 90 mg tabletiga
English: Each 30 mg tablet contains approximately 70 mg lactose (as monohydrate).
Estonian: Teadaolevat toimet omav(ad) abiaine(d) Üks 30 mg tablett sisaldab ligikaudu 70 mg laktoosi (monohüdraadina).
English: 14 tablets in 1 PVC/aluminium foil blister in wallet card with 7 × 30 mg and 7 × 60 mg tablets 28 tablets in 2 PVC/aluminium foil blisters in wallet card with 7 × 30 mg and 7 × 60 mg tablets 56 tablets in 4 PVC/aluminium foil blisters in wallet card with 7 × 30 mg and 7 × 60 mg tablets
Estonian: 14 tabletti 1 PVC/alumiiniumfooliumist blistris 7 × 30 mg ja 7 × 60 mg tabletiga 28 tabletti 2 PVC/alumiiniumfooliumist blistris 7 × 30 mg ja 7 × 60 mg tabletiga 56 tabletti 4 PVC/alumiiniumfooliumist blistris 7 × 30 mg ja 7 × 60 mg tabletiga
English: 14 tablets in 1 PVC/aluminium foil blister in wallet card with 7 × 30 mg and 7 × 90 mg tablets 28 tablets in 2 PVC/aluminium foil blisters in wallet card with 7 × 30 mg and 7 × 90 mg tablets 56 tablets in 4 PVC/aluminium foil blisters in wallet card with 7 × 30 mg and 7 × 90 mg tablets
Estonian: 14 tabletti 1 PVC/alumiiniumfooliumist blistris voldikpakendis 7 × 30 mg ja 7 × 90 mg tabletiga 28 tabletti 2 PVC/alumiiniumfooliumist blistris voldikpakendis 7 × 30 mg ja 7 × 90 mg tabletiga 56 tabletti 4 PVC/alumiiniumfooliumist blistris voldikpakendis 7 × 30 mg ja 7 × 90 mg tabletiga
English: 7 × 30 mg tablets and 7 × 60 mg tablets in card packaging 14 × 30 mg tablets and 14 × 60 mg tablets in card packaging 28 × 30 mg tablets and 28 × 60 mg tablets in card packaging
Estonian: 7 × 30 mg tabletti ja 7 × 60 mg tabletti voldikpakendis 14 × 30 mg tabletti ja 14 × 60 mg tabletti voldikpakendis 28 × 30 mg tabletti ja 28 × 60 mg tabletti voldikpakendis
English: Jinarc 30 mg tablets + Jinarc 90 mg tablets EU/1/15/1000/011-013 (blister) EU/1/15/1000/020-022 (blister in wallet card)
Estonian: Jinarc 30 mg tabletid + Jinarc 90 mg tabletid EU/1/15/1000/011-013
English: General disorders and administration site conditions
Estonian: Üldised häired ja manustamisko ha reaktsioonid
English: Otsuka Pharmaceutical Netherlands B.V. Thλ: +31 (0) 20 85 46 555
Estonian: Thλ: +31 (0) 20 85 46 555
English: The key secondary composite endpoint (ADPKD progression) was time to multiple clinical progression events of: 1) worsening kidney function (defined as a persistent [reproduced over at least 2 weeks] 25 %
Estonian: Põhiline teisene liittulemusnäitaja (autosoom-dominantse polütsüstilise neeruhaiguse progresseerumine) oli mitme kliinilise progresseerumise nähu tekkimiseni kulunud aeg:
English: Name
Estonian: Tugevus
English: Strength Pharmaceutical Form Route of Administration Packaging
Estonian: Ravimvorm Manustamistee
English: This summary was last updated in 07-2017.
Estonian: Kokkuvõtte viimane uuendus: 07-2017.
English: The standard dose is one 75-mg tablet once a day.
Estonian: Standardannus on üks 75 mg tablett üks kord ööpäevas.
English: The full EPAR for Clopidogrel TAD can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Clopidogrel TAD kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Clopidogrel TAD?
Estonian: Mis meetmed võetakse, et tagada ravimi Clopidogrel TAD ohutu ja efektiivne kasutamine?
English: clopidogrel
Estonian: klopidogreel
English: The European Commission granted a marketing authorisation valid throughout the European Union for Clopidogrel TAD on 23 September 2009.
Estonian: Euroopa Komisjon andis ravimi Clopidogrel TAD müügiloa, mis kehtib kogu Euroopa Liidus, 23. septembril 2009.
English: In acute coronary syndrome, treatment generally starts with a loading dose of four tablets.
Estonian: Ägeda koronaarsündroomi korral algab ravi üldiselt küllastusannusega 4 tabletti.
English: This is then followed by the standard 75-mg dose once a day for at least four weeks (in ‘ST segment elevation' myocardial infarction) or for up to 12 months (in unstable angina or ‘non-Q-wave' myocardial infarction).
Estonian: Seejärel jätkatakse standardannusega 75 mg ööpäevas vähemalt 4 nädalat (ST-segmendi elevatsiooniga infarkti korral) või kuni 12 kuud (ebastabiilse stenokardia või Q-sakita südameinfarkti korral).
English: It is used in those patients who have at least one risk factor for vascular events such as a heart attack or stroke, cannot take vitamin K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding.
Estonian: Ravim on näidustatud patsientidele, kellel on vähemalt üks vaskulaarhäirete, näiteks südameinfarkti või insuldi riskitegur, kes ei saa võtta K-vitamiini antagoniste (samuti antikoagulandid) ja kellel on väike verejooksurisk.
English: The Agency recommended that Clopidogrel TAD be approved for use in the EU.
Estonian: Ravimiamet soovitas ravimi Clopidogrel TAD kasutamise Euroopa Liidus heaks kiita.
English: • peripheral arterial disease (problems with blood flow in the arteries);
Estonian: • Perifeersete arterite haigus (arteriaalsed verevarustushäired).
English: In acute coronary syndrome and atrial fibrillation, Clopidogrel TAD is used together with aspirin, the dose of which should not be higher than 100 mg.
Estonian: Ägeda koronaarsündroomi ja kodade virvenduse korral võetakse ravimit Clopidogrel TAD koos aspiriiniga, mille annus ei tohi ületada 100 mg.
English: Clopidogrel TAD is available as tablets containing 75 mg clopidogrel.
Estonian: Ravimit Clopidogrel TAD turustatakse tablettidena, mis sisaldavad 75 mg klopidogreeli.
English: What is Clopidogrel TAD and what is it used for?
Estonian: Mis on Clopidogrel TAD ja milleks seda kasutatakse?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Clopidogrel TAD have been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Clopidogrel TAD ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: • recently had a myocardial infarction (heart attack).
Estonian: • Hiljuti esinenud südameinfarkt.
English: Acute coronary syndrome is a group of heart problems that include heart attacks and unstable angina (a severe type of chest pain).
Estonian: Äge koronaarsündroom on südamehaiguste rühm, kuhu kuuluvad südameinfarkt ja ebastabiilne stenokardia (rinnaangiin, teatud tugev rindkerevalu).
English: The European Medicines Agency concluded that, in accordance with EU requirements, Clopidogrel TAD has been shown to have comparable quality and to be bioequivalent to Plavix.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Clopidogrel TAD võrreldav kvaliteet ja bioekvivalentsus ravimiga Plavix.
English: Clopidogrel TAD can be started between seven days and six months after the stroke;
Estonian: Ravimi Clopidogrel TAD manustamist tohib alustada 7 päeva kuni 6 kuu jooksul pärast insulti.
English: Clopidogrel TAD is a ‘generic medicine'.
Estonian: Clopidogrel TAD on geneeriline ravim.
English: Because Clopidogrel TAD is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Clopidogrel TAD on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: This is a summary of the European public assessment report (EPAR) for Clopidogrel TAD.
Estonian: See on ravimi Clopidogrel TAD Euroopa avaliku hindamisaruande kokkuvõte.
English: This means that Clopidogrel TAD is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Estonian: See tähendab, et Clopidogrel TAD on sarnane võrdlusravimiga Plavix, millel juba on Euroopa Liidus müügiluba.
English: It is not intended to provide practical advice on how to use Clopidogrel TAD.
Estonian: Hindamisaruandes ei anta ravimi Clopidogrel TAD kasutamise praktilisi nõuandeid.
English: Therefore, the Agency's view was that, as for Plavix, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas amet, et nagu ka Plavixi korral, ületab ravimi Clopidogrel TAD kasulikkus sellega kaasnevad riskid.
English: For more information about treatment with Clopidogrel TAD, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Clopidogrel TAD toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Why is Clopidogrel TAD approved?
Estonian: Miks Clopidogrel TAD heaks kiideti?
English: This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.
Estonian: Nii ei kleepu trombotsüüdid kokku ja väheneb trombide tekke risk, millega ennetatakse järgmist infarkti või insulti.
English: For practical information about using Clopidogrel TAD, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Clopidogrel TAD kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: • atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with aspirin.
Estonian: • Kodade virvendus (südamekodade korrapäratu kiire kokkutõmbumine), mille korral tuleb ravimit võtta koos aspiriiniga.
English: Clopidogrel TAD can be started between a few days and 35 days after the attack;
Estonian: Ravimi Clopidogrel TAD manustamist tohib alustada mõne kuni 35 päeva jooksul pärast infarkti.
English: Because Clopidogrel TAD is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Estonian: Et Clopidogrel TAD on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati ravimi Clopidogrel TAD bioekvivalentsust võrdlusravimiga Plavix.
English: Other information about Clopidogrel TAD
Estonian: Muu teave ravimi Clopidogrel TAD kohta
English: Clopidogrel TAD contains the active substance clopidogrel.
Estonian: Clopidogrel TAD sisaldab toimeainena klopidogreeli.